Trichosanthin increases Granzyme B penetration into tumor cells by upregulation of CI-MPR on the cell surface
Metrics: PDF 604 views | HTML 967 views | ?
Chunman Li1, Meiqi Zeng1, Huju Chi1, Jing Shen2, Tzi-Bun Ng3, Guangyi Jin4, Desheng Lu4, Xinmin Fan4, Bilian Xiong1, Zhangang Xiao2, Ou Sha1
1Department of Anatomy, Histology and Developmental Biology, School of Basic Medical Sciences, Shenzhen University Health Science Centre, Shenzhen, Guangdong, China
2Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China
3School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
4School of Basic Medical Sciences, Shenzhen University Health Science Centre, Shenzhen, Guangdong, China
Ou Sha, email: firstname.lastname@example.org
Zhangang Xiao, email: email@example.com
Keywords: trichosanthin, granzyme B (GrzB), cation-independent mannose-6-phosphate receptor, tumor cells, immunotherapy
Received: December 23, 2016 Accepted: February 08, 2017 Published: February 19, 2017
Trichosanthin is a plant toxin belonging to the family of ribosome-inactivating proteins. It has various biological and pharmacological activities, including anti-tumor and immunoregulatory effects. In this study, we explored the potential medicinal applications of trichosanthin in cancer immunotherapy. We found that trichosanthin and cation-independent mannose-6-phosphate receptor competitively bind to the Golgi-localized, γ-ear containing and Arf-binding proteins. It in turn promotes the translocation of cation-independent mannose-6-phosphate receptor from the cytosol to the plasma membrane, which is a receptor of Granzyme B. The upregulation of this receptor on the tumor cell surface increased the cell permeability to Granzyme B, and the latter is one of the major factors of cytotoxic T lymphocyte-mediated tumor cell apoptosis. These results suggest a novel potential application of trichosanthin and shed light on its anti-tumor immunotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.